Salarius Pharmaceuticals Financing
Salarius Pharmaceuticals, Llc, Limited Liability Company just released form D because of $131,500 equity financing. This is a new filing. Salarius Pharmaceuticals was able to sell $131,500. That is 100.00% of the round of financing. The total financing amount was $131,500. The financing document was filed on 2016-11-21. The reason for the financing was: Proceeds will be used for working capital, which may include normal compensation to executive officers/managers..
Salarius Pharmaceuticals is based in Utah. The firm’s business is Pharmaceuticals. The form D was submitted by David J Arthur CEO. The company was incorporated more than five years ago. The filler’s address is: 5361 South 2110 East, Holladay, Ut, Utah, 84117. David J. Arthur is the related person in the form and it has address: 5361 South 2110 East, Holladay, Ut, Utah, 84117. Link to Salarius Pharmaceuticals Filing: 000166117816000003.
Analysis of Salarius Pharmaceuticals Offering
On average, startups in the Pharmaceuticals sector, sell 60.90% of the total offering amount. Salarius Pharmaceuticals sold 100.00% of the offering. Could this mean that the trust in Salarius Pharmaceuticals is high? The average investment size for companies in the Pharmaceuticals industry is $556,000. The offering was 76.35% smaller than the average of $556,000. Of course this should not be seen as negative. Businesses get financed for a variety of reasons and needs. The minimum investment for this offering was set at $0. If you know more about the reasons for the financing, please comment below.
What is Form D? What It Is Used For
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Salarius Pharmaceuticals Also
The Form D signed by David J Arthur might help Salarius Pharmaceuticals, Llc’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.